Research indicates indomethacin reduces RSV replication in human respiratory tract cells — Evidence Review
Published in Virus Research, by researchers from University Hospitals, Mount Sinai South Nassau
Researched by
— the AI search engine for science
Table of Contents
A laboratory study suggests that indomethacin, a widely used arthritis drug, significantly reduces RSV replication in human respiratory tract cells. Related studies generally support the potential antiviral or immunomodulatory effects of anti-rheumatic and NSAID drugs but emphasize that clinical relevance remains uncertain; see the original study source for more details.
- Several studies indicate that certain anti-rheumatic and NSAID drugs can modulate viral infections or immune responses, supporting the possibility that drugs like indomethacin may have off-target benefits in treating respiratory viral infections, including RSV and coronaviruses 1 2 3.
- However, related research also finds that not all NSAIDs have the same effects; for example, ibuprofen improved clinical outcomes in animal RSV models but did not reduce viral shedding, and some NSAIDs showed no increased risk of viral infection in humans 3 5 7 8.
- There is a consensus that while laboratory and animal model results are promising, more clinical research is needed to confirm antiviral efficacy and safety in humans, and findings in vitro or in animal models may not always translate to patient benefit 5 7 8.
Study Overview and Key Findings
Respiratory syncytial virus (RSV) remains a major cause of severe illness in infants and older adults, with limited treatment options available once infection occurs. The new study is timely because, despite preventive vaccines and antibody therapies, there is still no approved antiviral drug for RSV infection in humans. Indomethacin, an affordable and established anti-inflammatory medication, was investigated for potential antiviral activity against RSV, motivated by previous evidence of its effects against other viruses. The study's findings may have significant implications for repurposing existing drugs for RSV, but experts caution that laboratory data are only an initial step toward clinical application.
| Property | Value |
|---|---|
| Study Year | 2023 |
| Organization | University Hospitals, Mount Sinai South Nassau |
| Journal Name | Virus Research |
| Population | Human respiratory tract cells |
| Methods | In Vitro Study |
| Outcome | RSV replication and viral spread |
| Results | Indomethacin reduced RSV replication in human cells. |
Literature Review: Related Studies
To contextualize the new findings, we searched the Consensus research database, which covers over 200 million published papers. The following queries were used to identify relevant literature:
- indomethacin RSV replication reduction
- arthritis drug respiratory virus treatment
- non-steroidal anti-inflammatory RSV effects
Below, related studies are grouped by topic and summarized:
| Topic | Key Findings |
|---|---|
| Can anti-rheumatic or NSAID drugs provide antiviral benefits for respiratory viruses? | - Some anti-rheumatic drugs show potential antiviral activity, influencing treatment strategies for infections like COVID-19 and possibly RSV 1 2. - NSAIDs, including ibuprofen, demonstrate immunomodulatory effects in animal RSV models, improving clinical outcomes but not necessarily reducing viral replication or shedding 3 5 7 8. |
| Do NSAIDs or anti-inflammatory drugs increase or decrease the risk or severity of respiratory viral infections? | - Most NSAIDs do not increase the risk of acute viral respiratory infections, while certain immunosuppressive anti-rheumatic drugs may raise risk 3. - Ibuprofen and similar NSAIDs can improve clinical symptoms in RSV animal models, but may also increase viral shedding and do not always reduce lung pathology 5 7 8. |
| What are the mechanisms and safety profiles of anti-inflammatory drugs in respiratory viral infections? | - Indomethacin and aspirin, though similar as NSAIDs, may have different antiviral effects, with indomethacin showing unique activity against RSV in vitro [original study]. - Indomethacin is considered generally safe in short-term use, including in infants for specific conditions, but potential side effects exist with higher doses or prolonged use [original study, 3]. |
| How might drug combinations or alternative anti-inflammatory agents influence outcomes in RSV or related infections? | - Combining NSAIDs with antiviral agents (e.g., fusion protein inhibitors) can enhance clinical benefits in animal RSV models, especially when started early after infection 7 8. - Other anti-inflammatory compounds such as resveratrol and nicotinamide exhibit anti-inflammatory, but not necessarily antiviral, effects in experimental models 4 6. |
Can anti-rheumatic or NSAID drugs provide antiviral benefits for respiratory viruses?
Research indicates that certain anti-rheumatic and NSAID drugs possess antiviral or immunomodulatory properties, potentially offering benefits in the treatment of respiratory viral infections. While some anti-rheumatic drugs are being considered for COVID-19 management due to their immune-modulating effects, NSAIDs like ibuprofen have demonstrated the ability to improve clinical outcomes in RSV animal models. However, these benefits do not always extend to direct antiviral effects, such as reducing viral replication or shedding.
- Anti-rheumatic drugs have been investigated as potential COVID-19 treatments, influencing strategies for managing both infection and underlying diseases 1 2.
- Ibuprofen and similar NSAIDs improved clinical outcomes in animal RSV models, but did not always reduce viral load 5 7 8.
- There is a distinction between immunomodulation (improving symptoms) and direct antiviral effects (reducing viral replication) 5 7.
- Not all NSAIDs exhibit the same antiviral or clinical effects, highlighting the need for drug-specific research 3 5 7.
Do NSAIDs or anti-inflammatory drugs increase or decrease the risk or severity of respiratory viral infections?
Studies show that most NSAIDs do not increase the risk of respiratory viral infections, in contrast to some immunosuppressive anti-rheumatic drugs, which may elevate risk. In animal models, NSAIDs can mitigate clinical symptoms and modulate the immune response during RSV infection, but may also increase viral shedding and not significantly affect lung pathology.
- NSAIDs generally do not increase the risk of acute viral respiratory events in humans 3.
- Ibuprofen improved clinical scores and modulated immune markers in RSV-infected calves, but viral shedding was increased 5 7.
- The timing and combination of NSAID and antiviral therapy can influence both clinical and pathological outcomes 7 8.
- Some immunosuppressive anti-rheumatic drugs (e.g., high-dose glucocorticoids, JAK inhibitors) may increase susceptibility to viral infections 3.
What are the mechanisms and safety profiles of anti-inflammatory drugs in respiratory viral infections?
Indomethacin differs from other NSAIDs such as aspirin in its observed antiviral effect against RSV in vitro, suggesting a unique mechanism. The safety profile of indomethacin supports its short-term use, including in infants for certain conditions, but attention must be given to possible adverse effects with prolonged or high-dose use.
- Indomethacin, but not aspirin, inhibited RSV replication in vitro, indicating a mechanism separate from general NSAID action [original study].
- Indomethacin is used safely in neonates for specific cardiac indications, demonstrating a history of tolerability in infants [original study].
- Prolonged or high-dose NSAID use can carry risks such as kidney dysfunction or gastrointestinal side effects [original study, 3].
- Laboratory findings may not always translate to clinical efficacy, underlining the importance of further human studies [original study, 5,7,8].
How might drug combinations or alternative anti-inflammatory agents influence outcomes in RSV or related infections?
Combining NSAIDs with antiviral drugs, such as fusion protein inhibitors, has shown enhanced clinical benefit in animal RSV models, particularly when administered early after infection. Alternative anti-inflammatory compounds like resveratrol and nicotinamide demonstrate strong anti-inflammatory effects, but their direct antiviral properties are less clear.
- Dual therapy (NSAID plus antiviral) outperformed monotherapy in reducing clinical scores and some measures of lung injury in animal RSV studies 7 8.
- Early initiation of combination therapy was more effective than delayed treatment 7 8.
- Compounds like resveratrol and nicotinamide enhance anti-inflammatory responses but have not been shown to reduce viral replication in RSV models 4 6.
- These findings suggest a potential role for combination strategies in managing RSV, but also highlight the importance of distinguishing between symptom control and antiviral action 7 8.
Future Research Questions
Further research is necessary to determine whether indomethacin's antiviral effects observed in vitro can translate into clinical benefit for RSV-infected patients. Key areas for investigation include confirming efficacy and safety in human populations, elucidating the drug's mechanism of action against RSV, and exploring optimal dosing and timing. Additionally, studies should assess whether combining indomethacin with other treatments could enhance outcomes.
| Research Question | Relevance |
|---|---|
| Does indomethacin reduce RSV severity or duration in infected humans? | This question addresses the critical knowledge gap regarding whether indomethacin's antiviral effects in vitro translate to clinical benefit for patients with RSV. Clinical studies are needed to confirm efficacy and safety [original study, 5,7,8]. |
| What is the mechanism by which indomethacin inhibits RSV replication? | Understanding the molecular mechanism may help identify new drug targets or optimize therapy. The unique antiviral effect of indomethacin, compared to other NSAIDs, suggests a distinct pathway that warrants further investigation [original study, 3]. |
| How does indomethacin compare to other NSAIDs in RSV treatment? | This question explores whether the observed antiviral effects are unique to indomethacin or shared by other NSAIDs, informing clinical decision-making and potential drug repurposing strategies 3 5 7 8. |
| Is combination therapy with indomethacin and antivirals more effective than monotherapy for RSV? | Findings in animal models suggest combined approaches may improve outcomes; clinical studies could determine if similar benefits occur in humans 7 8. |
| What are the safety and side effect profiles of short-term indomethacin use for RSV in infants and older adults? | Safety is paramount, especially in vulnerable populations; while indomethacin is used in infants for other conditions, its safety profile in the context of RSV infection requires careful evaluation [original study, 3]. |